XML 48 R26.htm IDEA: XBRL DOCUMENT v3.22.4
Subsequent events
12 Months Ended
Dec. 31, 2022
Subsequent Events [Abstract]  
Subsequent events

19. Subsequent events

In February 2023, the Company completed enrollment of its Phase 3 placebo-controlled clinical trial for sepiapterin for PKU.  In connection with this event and in accordance with the Censa Merger Agreement, the Company is obligated to pay a $30.0 million development milestone to the former Censa securityholders, which the Company has the option to pay in cash or shares of its common stock.